These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 23665448)

  • 1. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
    Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
    J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
    Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
    J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric biopharmaceutics classification system: current status and future decisions.
    Batchelor H;
    Int J Pharm; 2014 Aug; 469(2):251-3. PubMed ID: 24602991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
    Zaki NM; Artursson P; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and applications of a physiologically-based model of paediatric oral drug absorption.
    Johnson TN; Bonner JJ; Tucker GT; Turner DB; Jamei M
    Eur J Pharm Sci; 2018 Mar; 115():57-67. PubMed ID: 29309876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.